Health agency The Leukemia & Lymphoma Society reported on Friday the receipt of the US Food & Drug Administration approval of gemtuzumab
ozogamicin (Mylotarg) for the treatment of acute myeloid leukemia, a deadly blood cancer.
B-cell lymphomas, the anti-CD33 antibody-drug conjugate gemtuzumab
ozogamicin, and the anti-CD123 antibody CSL362 in refractory AMLs; the anti-CD38 antibody daratumumab in plasma cell myeloma; and CD19-chimeric antigen receptor T cells in B-ALLs.
ozogamicin (GO) is a cluster of difference (CD33)-specific antibody and the first immunotherapy agent that has been tested for the treatment of AML.
Pharmacokinetics of Gemtuzumab
Ozogamicin, an Antibody Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse.
Monoclonal Infix Target Infix Source Suffix Antibody Name Transtuzumab Gemtuzumab
tu-Tumor zu-humanized -mab Infliximab Basiliximab li-Immune system xi-chimeric Omalizumab Daclizumab li-Immune cells zu-humanised Palivizumab vi-viral zu-humanised Denosumab s-Bone cells u-human Rituximab tu-Tumor xi-chimeric Icrucumab c-cardiovascular u-human Guselkumab k-interleukin u-human Fosinumab n-nerve u-human Blintumomab tum-Tumor cells o-murine lymphocytes
ozogamicin is an engineered humanized monoclonal IgG4 antibody directed against the CD33 antigen present on leukemic cells in 80% of patients with AML.
Patients given the new type of "smart drug" called Gemtuzumab
Ozogamicin (GO) as well as chemotherapy were 22% less likely to relapse and around 13% less likely to die from their disease.
Ozogamicin is the humanized anti CD33 antibody.
The research team studied more than 1,000 patients who received a combination of chemotherapy and the drug Gemtuzumab
Ozogamicin, which is also known as Mylotarg.
He was enrolled in a treatment protocol employing three days of daunorubicin, seven days of continuous infusion cytarabine, and one dose of gemtuzumab
The addresses of the institutions of the authors of the paper titled "Use of gemtuzumab
ozogamicin in the treatment of pediatric relapsed/refractory acute myleoid leukemia" which was published in Turkish Journal of Hematology Volume:25 Issue:1 Pages 36-41 were printed wrong due to the wrong information given by the authors.
Cytotoxic agents implicated in the development of hepatic SOS include busulfan, a common conditioning agent used in HSCT, and gemtuzumab
ozogamycin (Mylotarg[R], Wyeth Pharmaceuticals), an anti-CD33 monoclonal antibody.